Eledon director gets 3,430 shares from RSU vesting

Eledon Pharmaceuticals director Allan Kirk reported acquiring common shares through the vesting of equity awards.

Rhea-AI Filing Summary

Eledon Pharmaceuticals director Allan Kirk reported acquiring common shares through the vesting of equity awards. On January 10, 2026, 3,430 restricted stock units (RSUs) that had been granted on January 10, 2025 vested in full and were settled into 3,430 shares of Eledon Pharmaceuticals common stock on a one-for-one basis.

The RSU settlement was reported at a price of $0 per share, reflecting that no cash was paid in this conversion. Following the transaction, Allan Kirk beneficially owned 3,430 shares of common stock directly.

Insider Trade Summary

3,430 shares exercised/converted

Exercise 2 txns

Insider Kirk Allan

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	3,430	$0.00	$0.00
Exercise	Common Stock	3,430	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 3,430 shares (Direct)

Footnotes (1)

1. F1. Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026.

FAQ

What insider transaction did Eledon Pharmaceuticals (ELDN) disclose?

Eledon Pharmaceuticals disclosed that director Allan Kirk settled 3,430 restricted stock units into 3,430 shares of common stock on January 10, 2026.

How many Eledon Pharmaceuticals shares did Allan Kirk acquire in this Form 4?

Allan Kirk acquired 3,430 shares of Eledon Pharmaceuticals common stock through the settlement of 3,430 RSUs on a one-for-one basis.

What are the key dates for Allan Kirk's RSUs at Eledon Pharmaceuticals (ELDN)?

The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026, when they were settled into common shares.

Did Allan Kirk pay cash for the Eledon Pharmaceuticals shares received?

No. The Form 4 shows the RSU settlement into common stock at a price of $0 per share, indicating no cash payment for the shares.

How many Eledon Pharmaceuticals shares does Allan Kirk own after this transaction?

After the reported transaction, Allan Kirk beneficially owned 3,430 shares of Eledon Pharmaceuticals common stock directly.

What does transaction code "M" mean in Allan Kirk's Eledon Form 4?

Transaction code "M" indicates the exercise or conversion of a derivative security. Here it reflects the conversion of RSUs into common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/16/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kirk Allan

(Last) (First) (Middle)

C/O ELEDON PHARMACEUTICALS, INC.

19800 MACARTHUR BLVD STE. 250

(Street)

IRVINE CA 92612

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Eledon Pharmaceuticals, Inc. [ ELDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/10/2026		M		3,430(1)	A	$0	3,430	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/10/2026		M			3,430	(1)	(1)	Common Stock	3,430	$0	0	D

Explanation of Responses:

1. Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026.

	/s/ Paul Little, as attorney-in-fact for Allan Kirk, MD, PhD	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.